Although the homogeneous sample of patients with AD (prodromal or dementia) in this study was adequate in terms of size with respect to the main aim, the head-to-head comparison of the binding properties of the two tau-specific tracers, it limits the generalizability of the findings when describing the relationships with different biomarkers. The gene discussed is MAPT; the disease is Alzheimer disease.